1. Stanford V regimen in 59 patients (pts) with HD and HIV Infection (HD-HIV): A very effective approach in the long-term analysis
- Author
-
M. Spina, J. Gabarre, M. Fasan, A. Re, C. Schiantarelli, R. Talamini, E. Vaccher, and U. Tirelli
- Subjects
Cancer Research ,medicine.medical_specialty ,Pediatrics ,Adjuvant radiotherapy ,business.industry ,medicine.medical_treatment ,Human immunodeficiency virus (HIV) ,Phases of clinical research ,Stanford V regimen ,medicine.disease_cause ,Gastroenterology ,Prognostic score ,Stanford V ,Oncology ,Internal medicine ,Concomitant ,medicine ,Overall survival ,business - Abstract
7583 Background: The introduction of HAART has significantly improved the outcome of pts with HD-HIV. However there are no data on the long-term follow-up of HD-HIV pts treated with conventional chemotherapy (CT) regimens and concomitant HAART. In 2002, we reported the results of a prospective phase II study with the intensive 12-week CT with adjuvant radiotherapy (Stanford V) and concomitant HAART in 59 pts with HD-HIV, a well-known unfavorable subgroup of HD (Spina et al. Blood 2002; 100:1984–1988). Methods: To analyze the long-term outcome of patients included in the Stanford V and HAART protocol. Results: The median follow-up is 53 months (range 3–104 months The overall survival (OS) is 59%, the freedom from progression (FFP) is 62% and the disease free survival (DFS) is 72%. The 5-year probability of OS was significantly different in pts with an international prognostic score (IPS) 2 (84% vs 36%, p = 0.001). Similarly, the percentages of FFP at 5 years in these groups were 72% and 45% (p = 0.03). No significant side effects have been observed so far. Conclusions: After a median follow-up of 4.5 years, 72% of pts with this unfavorable subgroup and IPS No significant financial relationships to disclose.
- Published
- 2006
- Full Text
- View/download PDF